Steven N. Fishbane, MD
Chief, Division of Kidney Disease and Hypertension
Vice President, Northwell Health for Network Dialysis Services
Northwell Health
Manhattan, New York
Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York

Bruce S. Spinowitz, MD, FACP
Associate Director, Nephrology
Vice Chairman, Department of Medicine
NewYork Presbyterian-Queens
Professor of Clinical Medicine
Weill Cornell Medical College
New York, New York

Target Audience

This activity is intended for clinicians focused on nephrology, cardiology, and hematology.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss the prevalence and burdens of anemia associated with chronic kidney disease (CKD), including factors contributing to underdiagnosis and undertreatment
  • Explain the pathophysiologic processes underlying anemia associated with CKD, including potential therapeutic targets
  • Manage anemia in patients with CKD based on disease presentation, treatment response, and an understanding of the efficacy, safety, and other drawbacks of currently available therapies
  • Describe the mechanisms of action and clinical trial data associated with emerging treatment options for CKD-anemia

Program Overview

CKD affects more than 200 million people worldwide. A complication of CKD is the development of anemia, which has been linked to significant morbidity and mortality and becomes increasingly common among people with CKD as their disease progresses and affects nearly all patients who require dialysis yet is often undertreated. Given the general undertreatment of CKD-anemia and concerns with available therapeutic options, it is generally believed that new treatment approaches for increasing erythropoiesis are needed. Education that prepares physicians to incorporate these new therapies into practice will help to improve patient outcomes over time. This activity highlights the pathophysiology of CKD-anemia and addresses the rationale and clinical trial data for new approaches to treating this condition, with a focus on hypoxia-inducible factor prolyl hydroxylase inhibition.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Steven N. Fishbane, MD
Consultant/Independent Contractor: AstraZeneca plc; Grant/Research Support: Akebia Therapeutics, Inc., AstraZeneca plc

Bruce S. Spinowitz, MD, FACP
Consultant/Independent Contractor: Akebia Therapeutics, Inc., AstraZeneca, Bayer Corporation, Reata Pharmaceuticals, Inc.; Honoraria: Akebia Therapeutics, Inc., AstraZeneca plc, Reata Pharmaceuticals, Inc.; Speaker's Bureau: AstraZeneca plc, Fresenius Medical Care

The following planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Lindsay Borvansky; Andrea Funk; Liddy Knight; Ashley Cann; Julia Muino, MA; Gena Dolson, MS; Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your posttest will automatically be graded. If you successfully complete the posttest (score of 80% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 80%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Begin Activity